Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats-Reference-Cited by-同舟云学术

Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats

Published:2014-04-14 Issue:6 Volume:59 Page:2286-2298
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Verbeke Len¹,Farre Ricard²³,Trebicka Jonel⁴,Komuta Mina⁵,Roskams Tania⁵,Klein Sabine⁴,Elst Ingrid Vander¹,Windmolders Petra¹,Vanuytsel Tim²,Nevens Frederik¹,Laleman Wim¹

Affiliation:

1. Department of Liver and Biliopancreatic Disorders; University Hospital Gasthuisberg, University of Leuven; Leuven Belgium

2. Translational Research Center for Gastrointestinal Disorders; University of Leuven; Leuven Belgium

3. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd); Instituto de Salud Carlos II; Barcelona Spain

4. Department of Internal Medicine I; University of Bonn; Bonn Germany

5. Departments of Morphology and Molecular Pathology, Translational Cell and Tissue Research; University Hospitals Leuven; Leuven Belgium

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hep.26939/fullpdf

Reference56 articles.

1. Portal hypertension: from pathophysiology to clinical practice;Laleman;Liver Int,2005

2. Natural history of cirrhosis;Arsani;Curr Gastroenterol Rep,2013

3. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study;Jepsen;Hepatology,2010

4. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy;Laleman;Hepatology,2013

5. Propanolol for the prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study;Lebrec;N Engl J Med,1981

Cited by 237 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathophysiology and therapeutic options for cirrhotic portal hypertension;The Lancet Gastroenterology & Hepatology;2024-07

2. Inflammation in Steatotic Liver Diseases: Pathogenesis and Therapeutic Targets;Seminars in Liver Disease;2024-06-05

3. Total bile acids levels as a stratification tool for screening portopulmonary hypertension in patients with decompensated cirrhosis;Hepatology Research;2024-05-23

4. Functional metabolomics characterizes the contribution of farnesoid X receptor in pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome;Archives of Toxicology;2024-05-04

5. 3D‐Printed Lipid Mesophases for the Treatment of Chronic Liver Disease;Advanced Materials Technologies;2024-02-21